Dr. Scranton is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1620 Tremont Street
Brigham And Womens Hospital Division Of Aging
Boston, MA 02120Phone+1 617-525-7631
Education & Training
Naval Medical Center (Portsmouth)Residency, Internal Medicine, 1994 - 1997
East Tennessee State University James H. Quillen College of MedicineClass of 1994
Certifications & Licensure
MA State Medical License 2000 - 2018
Clinical Trials
- Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes Start of enrollment: 2004 Jul 01
- Efficacy and Safety of Cycloset® Compared With Placebo When Added to Metformin Start of enrollment: 2005 Feb 01
Publications & Presentations
PubMed
- A novel long-acting formulation of oral buprenorphine/naloxone produces prolonged decreases in fentanyl self-administration by rhesus monkeys.Richard W Foltin, Stephen Zale, Kristine A Sykes, Nayana Nagaraj, Richard E Scranton
Drug and Alcohol Dependence. 2022-10-01 - 2 citationsErratum. Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes.J Michael Gaziano, Anthony H Cincotta, Christopher M O'Connor, Michael Ezrokhi, Dean Rutty
Diabetes Care. 2016-10-01 - 27 citationsTimed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes MellitusBindu Chamarthi, J. Michael Gaziano, Lawrence Blonde, Aaron I. Vinik, Richard E. Scranton
Journal of Diabetes Research. 2015-04-28
Press Mentions
Lyndra Therapeutics Doses First Clinical Trial Participant in Pivotal Study of Oral Weekly Risperidone (LYN-005) for Schizophrenia and Schizoaffective DisorderMay 9th, 2023- Lyndra Therapeutics’ Investigational Oral, Weekly Opioid Use Disorder Treatment LYN-014 Granted Fast Track Designation by FDAJuly 27th, 2021
- Lyndra Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for Lyndra’s Weekly Risperidone (LYN-005) for the Treatment of Adults with Schizophrenia and Other IndicationsJuly 19th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
